Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02661815 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02661815: Clinical Trial Phase 1 study, sponsored by Dana-Farber Cancer Institute.
NCT02661815 is a Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02661815, a Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Participants with Ovarian, Fallopian Tube, or Peritoneal Cancer that has recurred within 12 months of prior treatment that includes Platinum Chemotherapy are invited to take part in this study. This research study is studying a combination of a new chemotherapy drug called Ricolinostat together with the chemotherapy Paclitaxel and a drug called Bevacizumab as a possible treatment for this diagnosis.
Primary Outcome
Not assessed, the MTD was not reached as the study was terminated.
Interventions
- DRUG Bevacizumab
- DRUG Paclitaxel
- DRUG Ricolinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-06-15 |
| Est. Completion | 2017-07-28 |
| Phase | Phase 1 |
Why NCT02661815 stopped before completion
NCT02661815 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT02661815 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02661815 about?
NCT02661815 is a clinical study titled "A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer". Participants with Ovarian, Fallopian Tube, or Peritoneal Cancer that has recurred within 12 months of prior treatment that includes Platinum Chemotherapy are invited to take part in this study. This research study is studying a combination of a new chemotherapy drug called Ricolinostat together with...
What is the current status of trial NCT02661815?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-06-15. Estimated completion is 2017-07-28.
What interventions are being tested in trial NCT02661815?
The interventions under investigation include: Bevacizumab (DRUG), Paclitaxel (DRUG), Ricolinostat (DRUG).
Who is sponsoring clinical trial NCT02661815?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02661815's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI